BridgeBio Pharma's Data From ATTRibute-CM Open-Label Extension Study Shows 44.7% Reduction In All-Cause Mortality, 49.3% In Cardiovascular Mortality Versus Placebo-To-Acoramidis; Acoramidis Well-Tolerated With No Long-Term Safety Concerns

BridgeBio Pharma, Inc. (NASDAQ: BBIO) presented long-term data from the ATTRibute-CM open-label extension trial, showing a 44.7% reduction in all-cause mortality and a 49.3% reduction in cardiovascular mortality compared to placebo when treated with acoramidis. The data, which highlights the sustained clinical benefit of acoramidis through Month 54, was presented at the American College of Cardiology Annual Scientific Sessions and is published in JAMA Cardiology. Acoramidis is noted for being a selective small molecule, orally administered, near-complete transthyretin stabilizer with no long-term safety concerns reported.